arrow
R

Radosław Kempiński

Wroclaw Medical University
H指数:16
被引数:1,162

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

达瓦基妥格在溃疡性结肠炎患者中的疗效与安全性(RELIEVE UCCD):一项2b期、随机、安慰剂对照试验

2026-07-160
PRE
Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial

米利克zumab与中度至重度活动性溃疡性结肠炎中肠道急迫性新指标快速且持续的改善相关:LUCENT-URGE试验的28周结果

2026-05-010
OA
Impact of baseline disease duration on the efficacy of once-daily oral obefazimod in moderately to severely active ulcerative colitis: week 8 results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials

基线疾病持续时间对中度至重度活动性溃疡性结肠炎患者每日一次口服奥贝非齐模疗效的影响:ABTECT-1和ABTECT-2 III期双盲安慰剂对照诱导试验第8周结果

2026-01-010
PRE
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
2022-11-0140
PRE
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
LANCET
IF88.5
2021-06-01215
PRE
Standard versus Endocuff versus cap-assisted colonoscopy for adenoma detection: A randomised controlled clinical trial

标准与Endocuff与cap辅助结肠镜检测腺瘤: 一项随机对照临床试验

2021-02-1611
OAAI
Management of bleeding in patients hospitalized in the intensive cardiac care unit
2019-12-192
OA